GALECTO INC (GLTO) Stock Price & Overview
NASDAQ:GLTO • US36322Q2066
Current stock price
The current stock price of GLTO is 28.69 USD. Today GLTO is down by -0.76%. In the past month the price increased by 13.58%. In the past year, price increased by 608.4%.
GLTO Key Statistics
- Market Cap
- 1.728B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -17.62
- Dividend Yield
- N/A
GLTO Stock Performance
GLTO Stock Chart
GLTO Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to GLTO. When comparing the yearly performance of all stocks, GLTO is one of the better performing stocks in the market, outperforming 99.44% of all stocks.
GLTO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GLTO. GLTO has a great financial health rating, but its profitability evaluates not so good.
GLTO Earnings
GLTO Forecast & Estimates
10 analysts have analysed GLTO and the average price target is 44.88 USD. This implies a price increase of 56.43% is expected in the next year compared to the current price of 28.69.
GLTO Groups
Sector & Classification
GLTO Financial Highlights
Over the last trailing twelve months GLTO reported a non-GAAP Earnings per Share(EPS) of -17.62. The EPS increased by 51.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -147.58% | ||
| ROE | -197.88% | ||
| Debt/Equity | 0 |
GLTO Ownership
GLTO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GLTO
Company Profile
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. The company is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Company Info
IPO: 2020-10-29
GALECTO INC
Ole Maaloes Vej 3
Boston MASSACHUSETTS DK-2200 DK
CEO: Hans T. Schambye
Employees: 5
Phone: 13026587581
GALECTO INC / GLTO FAQ
What does GLTO do?
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. The company is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
What is the stock price of GALECTO INC today?
The current stock price of GLTO is 28.69 USD. The price decreased by -0.76% in the last trading session.
Does GALECTO INC pay dividends?
GLTO does not pay a dividend.
What is the ChartMill rating of GALECTO INC stock?
GLTO has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is GALECTO INC (GLTO) stock traded?
GLTO stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for GLTO stock?
GALECTO INC (GLTO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-17.62).